Biotech News

Voyager to Present at Upcoming Investor Conferences

Voyager Therapeutics (VYGR)Voyager TherapeuticsConference / presentation

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference: Fireside chat at 3:45 p.m. ET on Tuesday, September 8, 2026, in Boston, MA.

2026 Cantor Global Healthcare Conference: Fireside chat at 8:35 a.m. ET on Friday, September 11, 2026, in New York, NY.

Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat at 10:45 a.m. ET on Monday, September 14, 2026, in New York, NY.

Baird’s 2026 Global Healthcare Conference: Fireside chat at 7:55 a.m. ET on Tuesday, September 15, 2026, in New York, NY.

H.C. Wainwright 28th Annual Global Investment Conference: Fireside chat at 2:30 p.m. ET on Tuesday, September 15, 2026, in New York, NY.

A webcast of the Wells Fargo fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com . A replay of the webcast will be archived on the company’s website for at least 30 days.

About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Contacts Company and Investors: Trista Morrison, NACD.DC, tmorrison@vygr.com Media: Lisa Guiterman, [email protected]

Related news

VYGRVoyager Therapeutics2026-10-27 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

NTLAIntellia2026-10-29 12:00 EST

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

EDITEditas Medicine2026-10-14 13:00 EST

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

TNXPTonix Pharmaceuticals2026-11-04 12:00 EST

Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

RVPHReviva Pharmaceuticals2026-09-22 12:00 EST

Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference

CRSPCRISPR Therapeutics2026-09-08 12:30 EST

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

CRBUCaribou2026-11-04 14:00 EST

Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting

NERVMinerva Neuroscience2026-10-29 11:00 EST

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

Voyager Therapeutics

Neurologic Genetic Medicines Voyager Therapeutics develops genetic medicines for neurologic diseases using human genetics and novel delivery technology. Its pipeline includes wholly owned and partnered programs. TRACER Capsid Platform The TRACER platform discovers adeno-associated-virus capsids designed to reach the central nervous...

Recent company news

Stock data

Close
1.72 USD
Market cap
216.91M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States